Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial - E4599

被引：2
|
作者：
Sandler, AB
Gray, R
Brahmer, J
Dowlati, A
Schiller, JH
Perry, MC
Johnson, DH
机构：
[1] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] Case Western Reserve Univ, Cleveland, OH 44106 USA
[5] Univ Wisconsin, Madison, WI USA
[6] Univ Missouri, Ellis Fischel Canc Ctr, Columbia, MO USA
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80220-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [41] A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC).
    Koshy, S
    Herbst, RS
    Obasaju, CK
    Fossella, F
    Papadimitrakopoulou, V
    Pisters, KMW
    Blumenschein, G
    Peeples, BO
    Hong, WK
    Zinner, RG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 634S - 634S
  • [42] Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer
    Niho, Seiji
    Kunitoh, Hideo
    Nokihara, Hiroshi
    Horai, Takeshi
    Ichinose, Yukito
    Hida, Toyoaki
    Yamamoto, Nobuyuki
    Kawahara, Masaaki
    Shinkai, Tetsu
    Nakagawa, Kazuhiko
    Matsui, Kaoru
    Negoro, Shunichi
    Yokoyama, Akira
    Kudoh, Shinzoh
    Kiura, Katsuyuki
    Mori, Kiyoshi
    Okamoto, Hiroaki
    Sakai, Hiroshi
    Takeda, Koji
    Yokota, Soichiro
    Saijo, Nagahiro
    Fukuoka, Masahiro
    LUNG CANCER, 2012, 76 (03) : 362 - 367
  • [43] Randomized Phase III Trial of Docetaxel Plus Carboplatin with or without Levofloxacin Prophylaxis in Elderly Patients with Advanced Non-small Cell Lung Cancer The APRONTA Trial
    Schuette, Wolfgang
    Nagel, Sylke
    von Weikersthal, Ludwig Fischer
    Pabst, Stefan
    Schumann, Christian
    Deuss, Burkhard
    Salm, Thorsten
    Roscher, Katrin
    Dickgreber, Nicolas
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (12) : 2090 - 2096
  • [44] An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer
    Kaira, Kyoichi
    Imai, Hisao
    Souma, Ryousuke
    Sakurai, Reiko
    Miura, Yosuke
    Sunaga, Noriaki
    Kasahara, Norimitsu
    Tsukagoshi, Yusuke
    Koga, Yasuhiko
    Kitahara, Shinsuke
    Kotake, Mie
    Minato, Koichi
    Naruse, Ichiro
    Fukushima, Yasutsugu
    Hisada, Takeshi
    Ishizuka, Tamotsu
    ANTICANCER RESEARCH, 2019, 39 (05) : 2483 - 2491
  • [45] A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer
    Waples, J. M.
    Auerbach, M.
    Boccia, R.
    Wiggans, R. G.
    Steis, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] Phase II Clinical Trial of Genexol® (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer
    Kim, Han Jo
    Kim, Kyoung Ha
    Yun, Jina
    Kim, Se Hyung
    Kim, Hyun Jung
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Nam Su
    Lee, Kyu Taek
    Kim, Do-Jin
    Park, Seong-Kyu
    Won, Jong-Ho
    Hong, Dae Sik
    Park, Hee Sook
    CANCER RESEARCH AND TREATMENT, 2011, 43 (01): : 19 - 23
  • [47] Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): Analyses based on age in the phase III PointBreak and E4599 trials
    Langer, Corey J.
    Socinski, Mark A.
    Patel, Jyoti D.
    Sandler, Alan
    Schiller, Joan H.
    Leon, Larry
    Uttamsingh, Shailaja
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Randomized phase II trial of pemetrexed with or without bevacizumab maintenance after cisplatin, pemetrexed and bevacizumab in advanced non-squamous, non-small cell lung cancer (TORG1321)
    Kondo, T.
    Kasai, T.
    Mori, K.
    Saito, H.
    Nishikawa, K.
    Otsu, S.
    Seki, N.
    Ichikawa, Y.
    Bessho, A.
    Tanaka, H.
    Yamaguchi, H.
    Kaburagi, T.
    Kanazawa, K.
    Komase, Y.
    Minato, K.
    Misumi, Y.
    Morinaga, R.
    Mori, K.
    Ohtake, J.
    Okamoto, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S875 - S875
  • [49] A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): Update of the Alpha Oncology trial (A1-99002L).
    Treat, J
    Belani, CP
    Edelman, MJ
    Socinski, MA
    Ansari, RH
    Obasaju, CK
    Bloss, JD
    Marinucci, DM
    Catalano, RB
    Comis, RL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1096S - 1096S
  • [50] A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC).
    Blumenschein, GR
    Khuri, F
    Gatzemeier, U
    Miller, WH
    von Pawel, J
    Rigas, JR
    Herbst, RS
    Dziewanowska, Z
    Negro-Vilar, A
    Mabry, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1094S - 1094S
12345